National Institutes of Health, a Component of the US Dept. of Health & Human Services

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Institute for Research in Biomedicine

US Government As Represented by the Secretary of the Army

The Scripps Research Institute

Southwest Research Institute

Dartmouth College

Michael Gordon Joyce

Yongping Yang

Baoshan Zhang

Barney S Graham

Peter D Kwong

Masaru Kanekiyo

Guillaume Stewart-Jones

Ivelin Georgiev

Marie Pancera

Tongqing Zhou

Aliaksandr Druz

Man Chen

Mallika Sastry

John R Mascola

Jason Scott McLellan

Gwo-Yu Chuang

Yaroslav Tsybovsky

Jason Gorman

Ulrich Baxa

Cinque Soto

Cheng Cheng

Jeffrey C Boyington

Wing-Pui Kong

Joseph Van Galen

Antonio Lanzavecchia

Peter L Collins

Davide Corti

Ursula J Buchholz

Jeffrey I Cohen

Wei Bu

John Mascola

Li Ou

Gilad Ofek

Sanjay Srivatsan

Kizzmekia S Corbett

Kai Xu

Paul Thomas

Lei Chen

Nianshuang Wang

Syed M Moin

Wing-pui Kong

Priyamvada Acharya

Emily Rundlet

Rita Chen

Joseph A McDonough

Hadi M Yassine

Wei Shi

Lingshu Wang

Andrew B Ward

Hannah Turner

Kayvon Modjarrad

Rajeshwer Singh Sankhala

Robert Kirchdoerfer

Christopher Cottrell

Jesper Pallesen

Allen Duplantier

Rekha Panchal

Robert Francis Campbell

Nadean M Gutierrez

Jonathan A Bohmann

Rebecca M Lynch

Rui Kong

Kevin Liu

Jason S Mclellan

Ivelin Stefanov Georgiev

Rebecca Lynch

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus (EBV) infection in mammals, and methods of using those compositions of matter for the detection, diagnosis and treatment of EBV infection are described. Also described are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

Prefusion RSV F proteins and their use

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Recombinant metapneumovirus f proteins and their use

HIV-1 Env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the HIV-1 Env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to HIV-1 in a subject. In additional embodiments, the therapeutically effective amount of the HIV-1 Env ectodomain trimers can be administered to a subject in a method of treating or preventing HIV-1 infection.

Recombinant HIV-1 envelope proteins and their use

Anti-EBV gH antibodies, anti-EBV gL antibodies, anti-EBV gH/gL antibodies, and compositions of matter useful for the detection, diagnosis, prevention, and treatment of Epstein Barr Virus infection in humans, and methods of using those compositions of matter for the same.

Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.

Inhibitors for coronavirus

Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.

Prefusion coronavirus spike proteins and their use

Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Self-assembling insect ferritin nanoparticles

Antibodies and methods for the diagnosis and treatment of Epstein Barr Virus infection

Antiviral drugs targeting the N-terminal domain (NTD) of the spike receptor binding domain (RBD) and methods of treating a subject suffering from coronavirus.

Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD)

Recombinant metapneumovirus F proteins and their use

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

Growing community of inventors

Washington, DC, United States of America

Michael Gordon Joyce